Lnc‐IRF2‐3 and Lnc‐ZNF667‐AS1 were recently studied as a positive biomarker for many tumor cells. However, experimental studies found that they are associated with worse outcomes in B‐CLL. Click to show full abstract
Lnc‐IRF2‐3 and Lnc‐ZNF667‐AS1 were recently studied as a positive biomarker for many tumor cells. However, experimental studies found that they are associated with worse outcomes in B‐CLL.
               
Click one of the above tabs to view related content.